The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of ...
Medicus Pharma (MDCX) announced feedback from Type C meeting with United States Food and Drug Administration. The purpose of the Type C meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback